Osteoarthritis was previously thought of as ‘wear and tear’ as humans age, however there is increasing evidence to support an inflammatory theory. The NLRP3 inflammasome has been implicated in the pathogenesis of a number of arthritic disorders, producing proinflammatory cytokines and degradative enzymes such as IL-1β, TNF-α and MMP-3 which drive cartilage degeneration and synovial inflammation. This review aims to summarise the evidence of NLRP3 involvement in osteoarthritis. Currently, treatment options focus on management of the disease and to date there is no cure. The development of novel biomarkers for osteoarthritis could improve diagnosis, treatment and management. Importantly, this review provides detail on the involvement of the NLRP3 inflammasome in osteoarthritis pathology and how its members could act as potential biomarkers to assist clinical decisions.
McAllister, M., El Chemaly, M., Eakin, A. J., Gibson, D. S., & McGilligan, V. E. (2018). NLRP3 as a potentially novel biomarker for the management of osteoarthritis. Osteoarthritis and Cartilage, 26(5), 612–619. https://doi.org/10.1016/j.joca.2018.02.901